Patient reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC)
Background: Multiple new therapies are now approved for patients (pts) with advanced RCC. As these agents enter widespread use, their perceived toxicities may differ from those reported in the literature and limit treatment duration and clinical outcomes. Patient reporting of toxicities may more accurately identify side effects most relevant to pts.
Methods: In an effort to collect patient-reported side effects from RCC pts treated with novel therapies, an on-line survey was developed. RCC pts were recruited through the Kidney Cancer Association.
Results: 177 pts completed the survey and 146 (64%M/36%F) received medication for RCC. Most common geographical regions were Midwest (20.8%); Northeast (17.4%); South/Southeast (16.7%); West (11.8%); and outside the
Conclusions: These results suggest that the patient-reported impact of molecularly targeted agent side effects may be more significant than suggested by phase III clinical trials. These results also identify specific side effects towards which improved symptom management strategies and enhanced patient education can be directed. Better side effect management may increase treatment duration and improve clinical outcomes.